Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bausch Health Companies Inc (BHC)

Bausch Health Companies Inc (BHC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,483,083
  • Shares Outstanding, K 358,396
  • Annual Sales, $ 8,027 M
  • Annual Income, $ -560,000 K
  • 60-Month Beta 1.70
  • Price/Sales 1.32
  • Price/Cash Flow 3.17
  • Price/Book N/A
Trade BHC with:

Options Overview

Details
  • Implied Volatility 45.17%
  • Historical Volatility 32.74%
  • IV Percentile 35%
  • IV Rank 14.18%
  • IV High 129.71% on 09/04/20
  • IV Low 31.21% on 07/02/21
  • Put/Call Vol Ratio 0.26
  • Today's Volume 3,402
  • Volume Avg (30-Day) 9,320
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 321,304
  • Open Int (30-Day) 359,860

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.97
  • Number of Estimates 5
  • High Estimate 1.02
  • Low Estimate 0.94
  • Prior Year 0.47
  • Growth Rate Est. (year over year) +106.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.72 +9.49%
on 07/19/21
30.30 -3.47%
on 07/02/21
-0.07 (-0.24%)
since 06/30/21
3-Month
26.72 +9.49%
on 07/19/21
32.54 -10.11%
on 06/01/21
-2.92 (-9.08%)
since 04/30/21
52-Week
14.86 +96.84%
on 09/30/20
34.80 -15.95%
on 03/09/21
+10.40 (+55.17%)
since 07/30/20

Most Recent Stories

More News
Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Recipients

/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the...

BHC : 29.25 (-1.15%)
BHC.TO : 36.50 (-1.00%)
Why Bausch (BHC) is Poised to Beat Earnings Estimates Again

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BHC : 29.25 (-1.15%)
Salix Announces 2021 Gastrointestinal Health Scholars Program Winners

/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies...

BHC : 29.25 (-1.15%)
BHC.TO : 36.50 (-1.00%)
Ardelyx (ARDX) Tumbles Following Deficiencies in Tenapanor NDA

The FDA notes deficiencies in the NDA seeking approval for Ardelyx's (ARDX) lead pipeline candidate, tenapanor, as a potential treatment for hyperphosphatemia.

IRWD : 13.27 (+0.84%)
ABBV : 116.30 (-2.16%)
ARDX : 1.7400 (+1.75%)
BHC : 29.25 (-1.15%)
Bausch + Lomb Will Present 14 Scientific Posters Featuring New Analyses Involving Its Surgical Technologies At The 2021 Annual Meeting Of The American Society Of Cataract And Refractive Surgery

/PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the presentation of 14 scientific posters involving...

BHC : 29.25 (-1.15%)
BHC.TO : 36.50 (-1.00%)
Bausch + Lomb Launches Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes

/PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the U.S. launch of Biotrue Hydration Boost Lubricant...

BHC : 29.25 (-1.15%)
BHC.TO : 36.50 (-1.00%)
4 Healthcare Stocks to Buy for Growth and Value

Bausch Health Companies (BHC), Regeneron Pharmaceuticals (REGN), Orthofix Medical (OFIX), and Alkermes (ALKS) are 4 healthcare stocks with strong value and growth qualities. These are a good fit for the...

REGN : 574.61 (-1.46%)
BHC : 29.25 (-1.15%)
OFIX : 39.74 (+1.53%)
ALKS : 25.87 (+1.21%)
Bausch + Lomb Completes Enrollment Of Second Phase 3 Study For NOV03 (perfluorohexyloctane)

and , , /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), and Novaliq GmbH, a biopharmaceutical company...

BHC : 29.25 (-1.15%)
BHC.TO : 36.50 (-1.00%)
Bausch Health Companies Inc. Will Release Second-Quarter 2021 Financial Results On August 3

/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter 2021 financial results on . Bausch Health will host a conference call and live web cast at...

BHC : 29.25 (-1.15%)
BHC.TO : 36.50 (-1.00%)
Bausch Health To Reduce Debt By $150 Million Using Cash Generated From Operations

/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by through the redemption of outstanding senior notes, using cash generated...

BHC : 29.25 (-1.15%)
BHC.TO : 36.50 (-1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Bausch Health Companies Inc. develops and distributes drugs. It develops drugs for unmet medical needs in central nervous system disorders and distributes generic and branded generic drugs primarily in Latin America and Eastern Europe. Bausch Health Companies Inc., formerly known as Valeant Pharmaceuticals,...

See More

Key Turning Points

3rd Resistance Point 30.10
2nd Resistance Point 29.87
1st Resistance Point 29.56
Last Price 29.25
1st Support Level 29.02
2nd Support Level 28.79
3rd Support Level 28.48

See More

52-Week High 34.80
Last Price 29.25
Fibonacci 61.8% 27.18
Fibonacci 50% 24.83
Fibonacci 38.2% 22.48
52-Week Low 14.86

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar